Thank you!

Thank you to our esteemed speaker delegation, conference attendees, sponsors and exhibitors for making Immuno-Oncology Summit 2019 a fantastic event! This year’s event hosted over 600 international scientists and executives, 50 scientific poster presentations, 37 exhibiting companies, and 23 sponsoring companies hailing from the United States and 18 other countries. Big Pharma and Biotech remain top participants (70%), though we saw a more diverse audience in 2019 with Healthcare Providers (10%), Government/Financial/CROs (8%) and Academics (7%) coming together to share knowledge and advance the challenges and opportunities facing the IO Industry.

View 2019 On-Site Photos

Join us August 10-14, 2020 at the Westin Copley Place in Boston, MA for the 8th Annual Immuno-Oncology Summit.

Be sure to visit for event updates including the call for 2020 speaker proposals, new content and event features, and other event updates. To plan out your 2020 Sponsor & Exhibitor calendar please contact Rod Eymael - Manager, Business Development at 781-247-6286.

Thank you again for making this year’s event such a success - We hope to see you again in 2020!

Best Regards,

The Immuno-Oncology Summit Team

About the Immuno-Oncology Summit

Over the past 7 years, CHI's Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline. Every year, we assemble an international mix of thought leaders and decision makers from industry and academia to bring you the latest developments in immuno-oncology, while providing access to a comprehensive 5-day program and extensive networking opportunities that CHI's IO Summit provides.

After extensive research with industry insiders, we have identified these “TOP TEN” key growth areas in immuno-oncology for 2019, which are reflected throughout the upcoming program. VIEW TOP TEN HERE.

The IO Summit is a perfect meeting place to share experience, foster collaborations, evaluate emerging technologies, and drive innovation in your immuno-oncology programs. Now in its 7th year, the IO Summit consistently delivers a cutting-edge agenda, 675+ senior delegates, and a sold-out exhibit hall. Whether you are an industry veteran or new adopter, researcher or business developer, scientist or CEO, this is one Immuno-Oncology event you don’t want to miss. If it’s important in 2019, it’s covered! Learn more.


Featured Speakers

Litao Zhang, Vice President, Leads Discovery and Optimization, Bristol-Myers Squibb


Neeraj Adya, PhD, Director, Pharmacodiagnostics, Bristol-Myers Squibb

John Desjarlais, PhD, Senior Vice President, Research, CSO, Xencor

Pamela Carroll, PhD, Senior Vice President, Immuno-Oncology, Genocea

Jianda Yuan, MD, PhD, Senior Director, Translational Oncology, Merck

Andrew Allen, President and CEO, Gritstone Oncology

Michael Woo, Head, Immuno-Oncology, Business Development, Novartis

Catherine Sabatos-Peyton, Director, Exploratory Immuno-Oncology, Novartis

Cokey Nguyen, Senior Director, Oncology R&D, Pfizer

Jon Wigginton, Senior Vice President & CMO, MacroGenics

Adrian Bot, Vice President, Translational Sciences, Kite, a Gilead Company

Tara Arvedson, PhD, Director, Oncology Research, Amgen

Philip Arlen, President & CEO, Precision Biologics

Arthur Krieg, Founder & CSO, Checkmate Pharmaceuticals

Kevin R. Webster, Senior Vice President, eFFECTOR Therapeutics

Stephen Doberstein, Chief Research and Development Officer, Nektar Therapeutics

David Kirn, Co-Founder & Executive Chairman, IGNITE Immunotherapy

Kathryn McCabe, Senior Director, Emerging Technology and Innovation, Eli Lilly

Scott M. DeWire, Global Head, Business Development and Licensing, Boehringer Ingelheim


Melinda Griffith, JD, Vice President, Strategic Alliances; Chief Legal Counsel, Parker Institute for Cancer Immunotherapy

Caron Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana Farber Cancer Institute

Howard Kaufman, PhD, CMO, Replimune

Paola Grandi, PhD, CSO, Cold Genesys

Preet M. Chaudhary, MD, PhD, Chief of Hematology, University of Southern California Keck School of Medicine

John Quackenbush, PhD, Chair, Department of Biostatistics, Harvard T.H. Chan School of Public Health

Why attend CHI’s Immuno-Oncology Summit?

with 675+ IO thought leaders from 28 countries and 400 companies

the latest developments in immuno-oncology from 175+ scientific presentations and 40+ posters

your comprehensive 5-day program by selecting from 12-tracks, 2 training seminars, 1 partnering forum and 1 course

at the industry’s leading Immuno-Oncology meeting, with 72% of delegates from biotech and pharma

and build lasting business relationships with IO decision-makers: 46% of delegates are executive/director level

your projects with technology solutions from 40+ exhibitors and 20+ technical presentations

actionable solutions at the expertly-facilitated roundtable discussions

on your agenda by track hopping between concurrent tracks

your research by presenting a scientific poster

Emerging Company Showcase

The Immuno-Oncology Investing and Partnering Forum will play host to an Emerging Company Showcase as part of the program agenda. This showcase allows immuno-oncology companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field.


Connect With Us


For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute


For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286


For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415